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Background and aims: We investigated whether plasma cystatin C (CysC) and neutrophil gelatinase-
associated lipocalin (NGAL) are associated with intravascular ultrasound (IVUS)-derived characteristics
of coronary atherosclerosis and 1-year adverse coronary events in patients with normal and mildly-to-
moderately impaired kidney function.
Methods: Between 2008 and 2011, virtual histology (VH)-IVUS of a non-culprit coronary artery was
performed in 581 patients undergoing coronary angiography. Creatinine, CysC and NGAL were measured
in pre-procedural blood samples. Presence of VH-IVUS-derived thin-cap ﬁbroatheroma (TCFA) lesions,
lesions with plaque burden (PB)70% and lesions with minimal luminal area (MLA)4 mm2 was
assessed. Major adverse coronary events (MACE) comprised the composite of all-cause mortality, acute
coronary syndrome, or unplanned coronary revascularization. Analyses were stratiﬁed using eGFRCr of
90 ml/min/1.73 m2 as the cut-off.
Results: In patients with normal kidney function, those with higher CysC levels had fewer lesions with
PB  70% and fewer VH-TCFA lesions (adjusted odds ratios (ORs) and 95% conﬁdence intervals (CIs): 0.46
[0.30e0.69] and 0.59 [0.44e0.83], respectively, per standard deviation (SD) ln[ng/mL] CysC). Those with
higher NGAL levels also had fewer lesions with PB  70% (adjusted OR [95% CI]:0.49 [0.29e0.82]) In
patients with impaired kidneys, no differences in high-risk lesions were observed for CysC or NGAL.
However, those with higher CysC had higher risk of MACE (hazard ratio (HR):1.4, 95% CI [1.03e1.92]).
This was not the case in patients with normal kidney function. NGAL did not inﬂuence risk of MACE.
Conclusions: Mild-to-moderate kidney dysfunction modiﬁes the relationship between CysC and high-risk
coronary lesions. This has not been established before, and offers an explanation for the difference in
ﬁndings between experimental and epidemiologic studies.
© 2017 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Kidney impairment, as assessed by creatinine-based equations
of glomerular ﬁltration rate (eGFRCr), is associated with cardio-
vascular disease independently of established cardiovascular risk, Room Ba-561, P.O. Box 2040,
.
r Ireland Ltd. This is an open accesfactors [1]. In persons with mild kidney dysfunction (eGFRCr in the
range of 60e89 ml/min/1.73 m2), cystatin C (CysC) may outperform
eGFRCr as a predictor of adverse outcome. This is illustrated by the
fact that CysC displays a linear association with mortality in pa-
tients with such mild GFR reduction, while eGFRCr has a J-shaped
association with mortality, and risk only starts to rise when eGFRCr
falls beneath 60 ml/min/1.73 m2 [2,3]. Although some studies have
shown linear associations of eGFRCr with adverse outcome, these
associations were linear only in particular ranges of eGFRCrs article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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CysC is a cysteine protease inhibitor produced by most nucle-
ated cells, and can be detected in serum or plasma [5]. In in vitro
and animal experiments, a reduction of CysC correlated with
increased activity of cysteine proteases cathepsins K and S, which
led to breakdown of the elastic lamina in the blood vessel wall [6].
Altered CysC expression has been identiﬁed in diseases which
progress by extracellular proteolysis, such as atherosclerosis and
aortic aneurysms, and metastasis [7,8]. These experiments, point-
ing towards a favourable role for CysC, do not concur with the
positive associations of CysC with adverse outcomes found in
epidemiological studies. Studies on the in-vivo association between
plasma CysC and coronary atherosclerosis may provide further
insight into this discrepancy, but have not yet been performed.
Neutrophil gelatinase-associated lipocalin (NGAL) is a clinically
relevant biomarker in acute kidney injury [9] due to its marked
increase in plasma and urine after tubulo-interstitial kidney dam-
age [10]. Recently, overexpression of plasma NGAL has been found
in coronary plaques, where NGAL inhibits elimination of matrix
metalloproteinasee9 (MMP-9) [11,12]. MMP-9 is involved in
extracellular matrix degradation, herewith increasing the risk of
plaque rupture [13]. NGAL and NGAL/MMP-9 complex have been
shown to predict major adverse cardiovascular events in epidemi-
ological studies [14,15].
In spite of the above-described associations that have been
demonstrated between CysC, NGAL and adverse cardiac events, the
presence and shape of a relationship between plasma CysC, NGAL,
and coronary atherosclerosis have not yet been investigated in-
vivo. To the best of our knowledge, we are the ﬁrst to perform
such an investigation, and to herewith provide a link between
fundamental experiments and epidemiological studies. Speciﬁcally,
our study aimed to investigate whether plasma CysC and NGAL are
associated with IVUS-derived characteristics of in-vivo coronary
atherosclerosis and 1-year adverse coronary events in patients with
normal and mildly-to-moderately impaired kidney function.2. Materials and methods
2.1. Study population
We have previously described the design of The European
Collaborative Project on Inﬂammation and Vascular Wall Remod-
eling in Atherosclerosis - Intravascular Ultrasound (ATHEROREMO-
IVUS) [16]. In this study, we included 581 patients undergoing
diagnostic coronary angiography or percutaneous coronary inter-
vention (PCI) for acute coronary syndrome (ACS) or stable angina
pectoris (SAP) between 2008 and 2011 in the Erasmus MC, Rot-
terdam, the Netherlands. Following coronary angiography, intra-
vascular ultrasound (IVUS) of a non-culprit coronary artery was
performed. The human research ethics committee of Erasmus MC,
Rotterdam, the Netherlands has approved this study. All included
patients have signed informed consent, and the study protocol
conformed to the Declaration of Helsinki. This study is registered in
ClinicalTrials.gov (number: NCT01789411).2.2. Kidney function assessment
Estimated Glomerular Filtration Rate (eGFRCr) was assessed by
the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)
equation [17]. Patients were categorized according to eGFR by using
the modiﬁed deﬁnition from the National Kidney Foundation e
Kidney Disease Outcome Quality Initiative (K/DOQI) clinical prac-
tice guidelines [18]: normal (GFR90 ml/min/1.73 m2), mild (GFR60e89 ml/min/1.73 m2), moderate (GFR 30e59 ml/min/1.73 m2),
and severe (GFR 15e29 ml/min/1.73 m2) kidney dysfunction, and
kidney failure (GFR<15 ml/min/1.73 m2). No patients with kidney
failure were present in this study, and only one patient had eGFRCr
<30ml/min/1.73m2. The latter was excluded from further analyses.
Patients were stratiﬁed into those with normal kidney function and
those with mildly-to-moderately impaired kidney function, using
an eGFRCr of 90 ml/min/1.73 m2 as the cut-off value.
2.3. Biomarkers
Arterial blood was taken before the procedure and stored
at 80 C within 2 h. Samples were available in 570 patients. An
immunoturbidimetric high sensitivity assay (Roche Diagnostics
Ltd., Rotkreuz, Switzerland) on the Roche Cobas 8000 modular
analyser platformwas used in the ErasmusMC clinical laboratory to
measure the level of C-reactive protein (CRP) in serum samples. The
plasma EDTA samples were transported at a temperature of 80 C
to Myriad RBM, Austin, Texas, USA, where cystatin C and NGAL
concentrations were assessed by a validated multiplex assay
(Custom Human Map, Myriad RBM, Austin, Texas, USA). As a result
of the batch-wise handling of the samples, with an update of the
composition of the multiplex assay by the manufacturer in-
between two batches, cystatin C was measured in the full cohort
of 570 patients, and NGAL in a random subset of 473 patients. Both
laboratories were blinded to clinical and imaging data.
2.4. Grayscale and radiofrequency intravascular ultrasound (IVUS)
Following coronary angiography, we performed IVUS imaging of
the most proximal part of a non-culprit, non-treated coronary
vessel. The non-culprit vessel was selected based on the following
order: left anterior descending artery; right coronary artery; left
circumﬂex artery. We obtained all IVUS data by the Volcano s5/s5i
Imaging System (Volcano Corp., San Diego, CA, USA) using a
Volcano-Eagle-Eye Gold IVUS catheter of 20 MHz with an auto-
matic pullback system and a standard pullback speed of 0.5 mm/s.
Subsequently, an independent core laboratory (Cardialysis BV,
Rotterdam, the Netherlands) analysed IVUS images ofﬂine, blinded
for clinical and biomarker data. The IVUS virtual histology (IVUS-
VH) was assessed by pcVH 2.1 and qVH (Volcano Corp., San Diego,
CA, USA) software. In each frame, the external elastic membrane
and luminal borders were outlined (median interslice distance,
0.40 mm).
The degree (plaque volume and plaque burden) and composi-
tion of the atherosclerotic plaque were assessed. Plaque volume
was deﬁned as the total volume of the external elastic membrane
occupied by atheroma [19]. Plaque burden was deﬁned as the
plaque and media cross-sectional area divided by the external
elastic membrane cross-sectional area and is presented as a per-
centage (Fig. 1). A coronary lesion was deﬁned as a segment with a
plaque burden of more than 40% in at least three consecutive
frames [16]. The composition of the atherosclerotic plaque was
characterized into ﬁbrous, ﬁbro-fatty, dense calcium and necrotic
core [20]. Subsequently, three types of VH-IVUS high-risk lesions
were identiﬁed: 1. Thin-cap ﬁbroatheroma (TCFA) lesion: a lesion
with the presence of >10% conﬂuent necrotic core in direct contact
with the lumen; 2. A lesion with a plaque burden of 70%; 3. a
lesion with a minimal luminal area (MLA) of 4.0 mm2 [21].
2.5. Follow-up
Clinical follow-up started at inclusion and lasted one year. The
Fig. 1. Plasma cystatin C and presence of VH-IVUS high-risk coronary lesions. Images: courtesy of J. Ligthart and K. Witberg, Invasive Imaging, Dpt. of Cardiology, Erasmus MC.
(A) Lesion with plaque burden (PB) 70%. Plaque burden is deﬁned as plaque and media cross-sectional area (i.e., area between yellow contour and red contour) divided by external
elastic membrane cross-sectional area (contoured in red); (B) VH-IVUS derived thin-cap ﬁbroatheroma lesion (VH-TCFA), deﬁned as a lesion (i.e., plaque with a plaque burden >40%)
with presence of conﬂuent necrotic core >10% in direct contact with the lumen in at least three frames; (C) Odds ratio (OR) per standard deviation increase in ln-transformed
cystatin C with 95% conﬁdence interval (CI) for lesions with PB  70%. (D) Odds ratio (OR) per standard deviation increase in ln-transformed cystatin C with 95% conﬁdence
interval (CI) for VH-TCFA lesions. FI, ﬁbrous; FF, ﬁbro-fatty; NC, necrotic core, DC, dense calcium. a adjusted for age, gender. diabetes, hypertension, indication for angiography, C-
reactive protein.
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mortality, ACS, or unplanned coronary revascularization. ACS was
deﬁned as the clinical diagnosis of ST-segment elevation myocar-
dial infarction (STEMI), non-STEMI, or unstable angina pectoris
using the guidelines of the European Society of Cardiology [22,23].
Unplanned coronary revascularizations were deﬁned as unplanned
coronary artery bypass grafting or repeat percutaneous coronary
intervention. The secondary endpoint was the composite of all-
cause mortality or ACS. The endpoints were adjudicated by a clin-
ical event committee blinded for biomarker and IVUS data.
2.6. Statistical analysis
The Kolmogorov-Smirnov test was used to test distributions of
continuous variables for normality. CysC and CRP were not nor-
mally distributed and were ln-transformed for further analyses.
Categorical variables are presented as numbers and percentages.
Continuous variables that were normally distributed are presented
as mean ± standard deviation (SD); non-normally distributed
continuous variables are presented as median and interquartile
range (IQR). For reasons of uniformity, all biomarkers are presented
as median (IQR).
We examined the associations of plasma CysC and NGAL levelswith plaque burden, plaque volume, and the presence of high-risk
coronary lesions. Plaque volume was normalized for the imaged
segment length. We used linear regression and logistic regression
analyses with continuous ln-transformed CysC and NGAL concen-
trations consecutively as independent variables. To assess the effect
of kidney function, we included interaction terms (ln-transformed
CysC or NGAL, respectively, with dichotomized eGFRCr (above or
below 90 ml/min/1.73 m2)) into the logistic regression models.
Subsequently, we stratiﬁed all analyses on eGFRCr of 90 ml/min/
1.73 m2. To test whether effect estimates differed between patients
with ACS and patients with SAP, Z-tests for heterogeneity were
performed.
Cox proportional hazards regression analyses were performed
to evaluate the associations between CysC and NGAL and the clin-
ical study endpoints.
Age, gender, indication for coronary angiography, diabetes
mellitus, hypertension, and CRP concentration were considered as
potential confounders, and were therefore entered into the multi-
variable linear and logistic regression models. Multivariable
adjustment of Cox proportional hazards models was constrained
due to the number of clinical endpoints, and was therefore per-
formed in two steps. For MACE, in the ﬁrst step the adjustment
included age, gender, and indication for angiography; in the second
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Finally, we determined the cut-off values of CysC and NGAL that
carry the optimal discriminative ability with respect to presence of
high-risk coronary lesions and occurrence of MACE. For this pur-
pose, we drew receiver operating characteristic (ROC) curves and
calculated the Youden index (highest sum of sensitivity and
speciﬁcity 1) [24]. We considered only statistically signiﬁcant
associations.
All data were analysed with SPSS software (SPSS 20.0; IBM
Corp., Armonk, NY). All statistical tests were two tailed, and p
values < 0.05 were considered statistically signiﬁcant.Table 1
Baseline characteristics.
Variable Total
(n ¼ 570)
Patient characteristics
Age, years (mean ± SD) 61.5 ± 11.4
Men, n (%) 430 (75.4)
Diabetes mellitus, n (%) 99 (17.4)
Hypertension, n (%) 295 (51.8)
Hypercholesterolemia, n (%) 317 (55.6)
Smoking, n (%) 164 (28.8)
Positive family history, n (%) 293 (51.5)
Previous MI, n (%) 184 (32.3)
Previous PCI, n (%) 185 (32.5)
Previous CABG, n (%) 18 (3.2)
Previous stroke, n (%) 23 (4.0)
Peripheral artery disease, n (%) 36 (6.3)
History of heart failure, n (%) 19 (3.3)
Indication for coronary angiography
Acute coronary syndrome, n (%) 309 (54.2)
Myocardial infarction, n (%) 159 (27.9)
Unstable angina pectoris, n (%) 150 (26.3)
Stable angina pectoris, n (%) 261 (45.8)
Coronary artery diseasea
No signiﬁcant stenosis, n (%) 42 (7.4)
1-vessel disease, n (%) 301 (52.8)
2-vessel disease, n (%) 166 (29.1)
3-vessel disease, n (%) 61 (10.7)
PCI performed, n (%) 501 (87.9)
IVUS characteristics
Segment length (mm), median (IQR) 44.2 (33.7e55.4)
Plaque burden (%), median (IQR) 39.2 (29.9e46.4)
Presence of VH-TCFA, n (%) 239 (41.9)
Presence of PB  70%, n (%) 120 (21.0)
Presence of MLA 4 mm2 175 (30.7)
Renal function
eGFR (ml/min/1.73 m2) median (IQR)b,c 90 (77e98)
KDOQI classiﬁcationa, n (%)
GFR 90 ml/min/1.73 m2 291 (51.8)
GFR 60e89 ml/min/1.73 m2 231(41.1)
GFR 30e59 ml/min/1.73 m2 39 (6.9)
GFR <30 ml/min/1.73 m2 1 (0.1)
Serum biomarkers
NGAL (ng/mL) median (IQR)d 197.0 (143.0e254.0)
eGFRCr 90 ml/min/1.73 m2e 183.0 (143.0e227.0)
eGFRCr 30e89 ml/min/1.73 m2e 216.0 (148.0e293.2)
Cystatin C (ng/ml) median (IQR) 796.0 (691.0e923.0)
eGFRCr 90 ml/min/1.73 m2 732.0 (644.0e834.0)
eGFRCr 30e89 ml/min/1.73 m2 872.0 (775.7e1032.5)
Creatinine (umol/l), median (IQR)c 77 (66e86)
C-reactive protein (mg/l), median (IQR) 2.1 (0.8e5.3)
ACS, acute coronary syndrome; SAP, stable angina pectoris; CABG, coronary artery bypas
chronic kidney disease; NGAL, neutrophil gelatinase-associated lipocalin; PB, plaque bur
a Signiﬁcant stenosis was deﬁned as a stenosis >50% of the vessel diameter by visual
b Estimated Glomerular Filtration Rate (eGFRCr) using CKD-EPI equation: GFR¼ 141m
where: Scr is serum creatinine in mg/dL, k is 0.7 for females and 0.9 for males, a is0.329
indicates the maximum of Scr/k or 1.
c Creatinine available in 99%, total n ¼ 562, ACS n ¼ 304, SAP n ¼ 258.
d Measurable in sample of total n ¼ 473, ACS n ¼ 257, SAP n ¼ 216.
e A statistically signiﬁcant difference in plasma NGAL levels between ACS and SAP patie
30e89 ml/min/1.73 m2,p ¼ 0.03).3. Results
3.1. Baseline characteristics
Mean agewas 61.6 ± 11.4 years, 75.7% were men, 54.6% had ACS,
and 45.4% had SAP (Table 1). The imaged coronary segment had a
median length of 44.3(33.8e55.4) mm. A total of 239 (41.5%) pa-
tients had at least one TCFA lesion, 120 (21.0%) had lesions with
PB  70%, and 175 (30.7%) had lesions with MLA4 mm2. Median
eGFRCr was 90 (77e98) ml/min/1.73 mm2 in the full cohort with
similar values in the subset of ACS patients (91[78e100] ml/min/ACS patients
(n ¼ 309)
SAP patients
(n ¼ 261)
59.7 ± 11.9 63.6 ± 10.3
227 (73.5) 203 (77.8)
40 (12.9) 59 (22.6)
134 (43.4) 161 (61.7)
137 (44.3) 180 (69.0)
115 (37.2) 49 (18.8)
140 (45.5) 153 (58.6)
80 (25.9) 104 (39.8)
57 (18.4) 128 (49.0)
7 (2.3) 11 (4.2)
10 (3.2) 13 (5.0)
12 (3.9) 24 (9.2)
6 (1.9) 13 (5.0)
309 (100.0) 0 (0.0)
159 (51.5) 0 (0.0)
150 (48.5) 0 (0.0)
0 (0.0) 261 (100.0)
18 (5.8) 24 (9.2)
168 (54.5) 133 (51.0)
88 (28.5) 78 (29.9)
35 (11.3) 26 (10.0)
287 (92.9) 214 (82.0)
43.9 (32.9e54.1) 44.8 (34.2e57.2)
37.2 (28.0e45.5) 40.1 (31.8e47.7)
140 (45.5) 99 (37.9)
56 (18.1) 64 (24.5)
87 (28.2) 88 (33.7)
91 (78e100) 89 (77e97)
165 (54.3) 126 (48.8)
115 (37.8) 116 (45.0)
23 (7.6) 16 (6.2)
1 (0.3) 0 (0.0)
204.0 (148.2e274.5) 177.0 (141.5e239.0)
193.0 (143.0e243.0) 174.0 (125.0e223.0)
228.5 (149.0e307.0) 197.0 (143.5e257.7)
791.0 (674.5e915.5) 802.0 (712.5e935.5)
729.0 (637.5e841.5 734.5 (650.7e822.5)
863.0 (745.0e1040.0) 879.0 (781.0e1030.0)
77 (65e877) 76 (67e86)
2.8 (1.1e6.9) 1.4 (0.6e3.1)
s grafting; MI, myocardial infarction; PCI, percutaneous coronary intervention; CKD,
den; MLA, minimal luminal area.
assessment on the coronary angiogram.
in (Scr/k, 1)amax(Scr/k, 1)-1.209 0.993Age 1.018 [if female] 1.159 [if black]
for females and0.411 for males, min indicates the minimum of Scr/k or 1, and max
nts (for total population, p¼ 0.002; if eGFRCr90ml/min/1.73 m2, p¼ 0.01; if eGFRCr
Table 3
Plasma cystatin C, NGAL and segment characteristics (degree of atherosclerosis:
plaque volume and plaque burden; composition of coronary atherosclerosis: 4
components) as determined by VH-IVUS stratiﬁed according to kidney function
(eGFRCrj).
Cystatin Cb NGALc
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of 291 (51.8%) patients had normal kidney function and 271 (48.2%)
patients had mild-to-moderate kidney dysfunction. ACS patients
exhibited signiﬁcantly higher NGAL levels compared to patients
with SAP, regardless of kidney function, whereas plasma CysC levels
were similar in both eGFRCr groups (Table 1).b coefﬁcient (95% CI) p b coefﬁcient (95% CI) p
eGFRCr  90 ml/min/1.73 m2
Plaque burdena 0.02 (0.16e0.12) 0.77 0.05 (0.18e0.09) 0.50
Plaque volumea 0.43 (1.02e0.16) 0.16 0.19 (0.77e0.38) 0.51
FI (%) 0.52 (1.11e2.15) 0.53 0.60 (0.98e2.19) 0.45
FF (%)a 0.03 (1.10e0.17) 0.65 0.12 (0.02e0.25) 0.09
NC (%) 0.65 (1.84e0.53) 0.28 0.85 (2.00e0.30) 0.15
DC (%)a 0.00 (0.17e0.17) 0.99 0.12 (0.28e0.04) 0.15
eGFRCr 30e89 ml/min/1.73 m2
Plaque burdena 0.00 (0.11e0.12) 0.94 0.03 (0.15e0.09) 0.66
Plaque volumea 0.16 (0.37e0.68) 0.55 0.04 (0.59e0.51) 0.89
FI (%) 1.04 (2.45e0.37) 0.15 0.60 (0.89e2.09) 0.42
FF (%)a 0.02 (0.13e0.10) 0.76 0.01 (0.12e0.11) 0.92
NC (%) 0.44 (0.47e1.35) 0.34 0.27 (1.23e0.68) 0.57
DC (%)a 0.11 (0.04e0.25) 0.15 0.06 (0.21e0.09) 0.44
FI, ﬁbrous; FF, ﬁbro-fatty; NC, necrotic core, DC, dense calcium.
a Square root transformed.
b Unadjusted b coefﬁcient per standard deviation increase in ln-transformed
cystatin C with 95% conﬁdence interval (CI).
c Unadjusted b coefﬁcient per standard deviation increase in NGAL with 95%
conﬁdence interval (CI).3.2. Cystatin C, NGAL and degree of atherosclerosis on grayscale
IVUS
Numbers of lesions with plaque burden (PB) 70% and minimal
luminal area (MLA) 4 mm2 according to categories of kidney
function are depicted in supplementary Fig. 3. Signiﬁcant in-
teractions were found between CysC and eGFRCr in crude
(p ¼ 0.007) and multivariable (p ¼ 0.010) models predicting lesions
with PB  70%. In patients with normal kidney function, those with
higher CysC had lower risk of lesions with PB  70% (per SD in-
crease in ln-transformed CysC: OR [95% CI]: 0.56 [0.39e0.82],
p ¼ 0.002) (Table 2, Fig. 1A, C, Supplementary Fig. 1). After multi-
variable adjustment including CRP levels, risk remained signiﬁ-
cantly lower (adjusted OR [95% CI]: 0.46 [0.30e0.69], p < 0.001). A
CysC level of 773.0 ng/ml was the optimal cut-off value to identify
patients who did not have lesions with PB  70% (CysC 773.0 ng/
ml) (Supplementary Fig. 4). Conversely, in patients with mild-to-
moderate kidney dysfunction risk did not differ signiﬁcantly ac-
cording to CysC levels (adjusted OR [95% CI]:0.95 [0.69e1.30],
p ¼ 0.75). Risk of lesions with PB  70% displayed a similar pattern
in patients with higher NGAL (Table 2). In patients with normal
kidney function, an NGAL level of 180.0 ng/ml was the optimal cut-
off value to identify patients without lesions with PB  70% (NGAL
180.0 ng/ml) (Supplementary Fig. 5). Risk of lesions with MLA
4 mm2 was not different for patients with higher CysC or NGAL
(Table 2).
Overall, no differences could be demonstrated between CysC
and NGAL in either plaque burden or normalized plaque volume ofTable 2
Plasma cystatin C, NGAL and presence of thin-cap ﬁbroatheroma (VH-TCFA) lesions,
lesions with plaque burden (PB) 70% and lesions with minimal luminal area (MLA)
4 mm2 stratiﬁed according to kidney function (eGFRCrj).
Unadjusted model Multivariable model
OR (95% CI) p OR (95% CI) p
eGFRCr  90 ml/min/1.73 m2
VH-TCFA
Cystatin Ca 0.63 (0.46e0.85) 0.002 0.59 (0.44e0.83) 0.002
NGALb 0.77 (0.57e1.04) 0.090 0.72 (0.52e0.98) 0.040
Plaque burden ≥ 70%
Cystatin Ca 0.56 (0.39e0.82) 0.002 0.46 (0.30e0.69) <0.001
NGALb 0.56 (0.35e0.89) 0.015 0.49 (0.29e0.82) 0.007
MLA ≤ 4 mm2
Cystatin Ca 0.97 (0.72e1.32) 0.88 0.92 (0.67e1.25) 0.59
NGALb 1.03 (0.77e1.37) 0.84 1.07 (0.79e1.45) 0.67
eGFRCr 30e89 ml/min/1.73 m2
VH-TCFA
Cystatin Ca 1.14 (0.89e1.45) 0.30 1.09 (0.83e1.42) 0.55
NGALb 1.01 (0.78e1.29) 0.97 0.96 (0.74e1.24) 0.74
Plaque burden ≥ 70%
Cystatin Ca 1.06 (0.80e1.40) 0.68 0.95 (0.69e1.30) 0.75
NGALb 1.20 (0.88e1.63) 0.25 1.21 (0.87e1.67) 0.25
MLA ≤ 4 mm2
Cystatin Ca 0.84 (0.64e1.10) 0.19 0.73 (0.53e0.99) 0.042
NGALb 0.98 (0.74e1.29) 0.90 1.05 (0.78e1.41) 0.75
a Odds ratio (OR) per standard deviation increase in ln-transformed cystatin C
with 95% conﬁdence interval (CI).
b Odds ratio (OR) per standard deviation increase in NGAL with 95% conﬁdence
interval (CI); Multivariable model: adjusted for age, gender, diabetes mellitus, hy-
pertension, indication for angiography, C-reactive protein.the entirely imaged segment (Table 3 and Supplementary Table 2).
Nevertheless, CysC showed a tendency towards lower normalized
segment plaque volume (per SD increase in ln-transformed CysC: b
[95% CI]:0.43 [1.02e0.16], p ¼ 0.16) in patients with normal
kidney function; whereas no differences were observed in patients
with mild-to-moderate kidney dysfunction.
There was no heterogeneity between ACS and SAP patients
regarding the differences in IVUS grayscale parameters according to
CysC or NGAL levels.3.3. Cystatin C, NGAL and composition of atherosclerosis on
radiofrequency VH-IVUS
Numbers of thin-cap ﬁbroatheroma lesions (VH-TCFAs) ac-
cording to categories of kidney function are depicted in supple-
mentary Fig. 3. Signiﬁcant interactions were found between CysC
and eGFRCr in crude (p ¼ 0.002) and multivariable (p ¼ 0.003)
models predicting VH-TCFAs. In patients with normal kidney
function, those with higher CysC levels had lower risk of VH-TCFA
lesions (per SD increase in ln-transformed CysC: OR [95% CI]: 0.63
[0.46e0.85], p ¼ 0.002) (Table 2, Fig. 1B, D, Supplementary Fig. 1).
After multivariable adjustment including CRP levels, risk remained
signiﬁcantly lower (adjusted OR [95% CI]: 0.59 [0.44e0.83],
p ¼ 0.002). CysC of 678.5 ng/ml was the optimal cut-off value to
identify patients without VH-TCFA lesions (CysC 678.5 ng/ml)
(Supplementary Fig. 6). Conversely, in patients with mild-to-
moderate kidney dysfunction, risk did not differ signiﬁcantly ac-
cording to CysC levels (adjusted OR [95% CI]: 1.09 [0.83e1.42],
p ¼ 0.55). The interaction between NGAL and eGFRCr was not sta-
tistically signiﬁcant. A tendency towards lower risk of VH-TCFA
lesions was observed for higher NGAL, but only in patients with
normal kidney function (Table 2). There was no heterogeneity be-
tween ACS and SAP patients regarding the difference in VH-TCFA
lesions (CysC, p ¼ 0.29, NGAL, p ¼ 0.57) (Supplementary Table 1).
At the level of the entire segment, no differences were present in
radiofrequency VH-tissue types between CysC or NGAL (Table 3 and
Supplementary Table 2).
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Vital status was acquired for 569 (99.8%) patients. During the 1-
year follow-up, 56 patients experienced the primary endpoint
(MACE; Supplementary Fig. 3), and 30 patients endured the sec-
ondary composite endpoint of all-cause mortality or ACS. In the full
cohort, patients with higher CysC had higher risk of MACE (per SD
increase in ln-transformed CysC: HR [95% CI]:1.41 [1.10e1.79],
p ¼ 0.006) (Fig. 2, Supplementary Fig. 2). After multivariable
adjustment, the risk estimate lost statistical signiﬁcance. For NGAL,
signiﬁcant differences in risk of MACE were not found (Fig. 2,
Supplementary Fig. 2).
In patients with normal kidney function, those with higher CysC
levels did not have higher risk of MACE. (Fig. 2, Supplementary
Fig. 2). In patients with mild-to-moderate kidney dysfunction,
those with higher CysC levels had higher risk of MACE in uni-
variable analysis (HR [95% CI]:1.40 [1.03e1.92], p ¼ 0.03) (Fig. 2,
Supplementary Fig. 2). In multivariable analysis, the HR lost sta-
tistical signiﬁcance, but did not materially change (HR [95% CI]:1.31
[0.92e1.87], p ¼ 0.12).
Both in the total population and in patients with mild-to-
moderate kidney dysfunction, a CysC of 849.0 ng/ml was the
optimal cut-off value to identify patients who developed MACE
(CysC 849.0 ng/ml) (Supplementary Fig. 7).
Patterns of risk of the secondary endpoint (all-cause mortality
and ACS) according to CysC and NGAL levels were similar to those of
MACE (Supplementary Table 3).
Finally, stratiﬁcation on the indication for angiography
conﬁrmed the risk patterns which were found in the full cohort
(Supplementary Table 4).Fig. 2. Plasma cystatin C, NGAL and occurrence of the 1-year MACE. MACE, major
adverse coronary event; Hazard ratio (HR) per standard deviation increase in ln-
transformed cystatin C and per standard deviation increase in NGAL with 95% conﬁ-
dence interval (CI). aunadjusted model; b adjusted for age, gender, indication for
angiography; c adjusted for age, gender, indication for angiography, diabetes mellitus,
hypertension, C-reactive protein; multivariable adjustment was constrained by the
limited number of clinical endpoints.4. Discussion
We found that in patients with normal kidney function, those
with higher CysC levels had fewer high-risk coronary lesions (VH-
TCFA and lesions with PB  70%), while risk of MACE was not
different. Conversely, when kidney function was mildly-to-
moderately impaired, no differences in high-risk lesions were
observed, but those with higher CysC levels had higher risk of
MACE. Therefore, with regard to prediction of cardiovascular risk,
CysC appears to carry potential only when eGFRCr is below 90 ml/
min/1.73 m2. Furthermore, patients with higher NGAL levels had
fewer lesions with PB  70%, but only when they had normal kid-
ney function. No differences in MACE were found for NGAL, and
thus its use for cardiovascular risk prediction could not be sub-
stantiated. Altogether, our results on CysC suggest novel patho-
physiological insights, because they offer an explanation for the
difference in ﬁndings observed in experimental and epidemiologic
studies so far, and imply that the association between CysC and
cardiovascular disease may not be solely explained through its
correlation with GFR.
Higher CysC levels have been associated with occurrence of
cardiovascular events in various epidemiological studies [25].
Conversely, animal experiments suggest that higher CysC may be
favourable. Atherosclerotic mice deﬁcient in CysC display
increased plaque size and macrophage content, increased elastic
lamina degradation and accumulation of smooth muscle cells
[26,6]. Studies in humans have also found reduced CysC in
atherosclerotic and aneurysmatic aortic lesions [7]. Xu et al. have
demonstrated that immune cells (CD8þ dendritic cells (DC) and
macrophages), which are involved in atherosclerotic processes,
are major contributors to the circulating CysC pool [27,28]. How-
ever, besides a correlation with GFR, the mechanisms that may
explain the link between CysC and cardiovascular disease are still
unclear. Our study provides additional insights. We found that in
patients with normal kidney function, those with higher CysC
levels had fewer high-risk coronary lesions, and did not have
higher risk of MACE. This is in accordance with a potential ‘athero-
protective’ effect.
Conversely, in patients with mild-to-moderate kidney
dysfunction, differences in high-risk lesions according to CysC level
were not present. This could possibly be explained by the changes
in CysC physiology that occur in impaired kidneys. When kidney
function deteriorates, circulating plasma CysC increases and
oxidative stress advances, both of which stimulate Cys to form
homodimers [28,29]. When CysC forms homodimers, it cannot
inhibit cysteine proteases, because the inhibitory region is hidden
within the dimer interface. Thus, it may no longer be able to exhibit
‘athero-protective’ properties [30]. Although these hypotheses are
compelling, additional clinical and experimental studies are
necessary to further substantiate the effect modiﬁcation by kidney
function that we observed.
Our ﬁndings suggest that NGAL may act on coronary artery
disease through a different mechanism than currently investigated.
A potential lack of predictive precision due to a limited number of
MACE may explain the difference between the current results and
previous studies [15,31]. On the other hand, a recent meta-analysis
that investigated NGAL as a predictor of cardiovascular disease
concluded that strong evidence for independent predictive value of
NGAL is still lacking [32]. Notably, we found higher plasma NGAL
levels in ACS patients compared to SAP patients, independently of
kidney function. This could possibly be explained by neutrophilia as
a consequence of more severe cardiac damage in ACS patients
compared to SAP patients [33]. However, no heterogeneity between
ACS and SAP patients was observed in the relationship between
NGAL and IVUS-features of coronary atherosclerosis.
M. Brankovic et al. / Atherosclerosis 254 (2016) 20e2726Some limitations of this study merit consideration. This study is
currently the largest cohort inwhich the associations between IVUS
plaque characteristics, CysC and NGAL were investigated. Yet, we
cannot exclude the possibility of a chance ﬁnding with regard to
effect modiﬁcation by kidney function. However, both the cut-off
value (based on K/DOQI guidelines) and the study population (no
kidney failure/eGFR<30) were chosen a priori. Still, our ﬁndings
should be considered hypothesis-generating and warrant external
validation. Second, kidney function was determined by the
creatinine-based CKD-EPI formula, without direct measurement of
GFR. Although the CKD-EPI formula has displayed better perfor-
mance than the Modiﬁcation of Diet in Renal Disease (MDRD)
equation [17], it is still possible that a few patients aremisclassiﬁed.
Third, VH-IVUS imaging was limited to a pre-speciﬁed target
segment of a non-culprit coronary artery. This study design was
chosen based on the hypothesis that such a non-stenotic segment
reﬂects coronary wall pathophysiology of the larger coronary tree
[34,35]. This hypothesis, on its part, was based on ex-vivo, as well as
in-vivo studies using IVUS in patients with myocardial infarction.
These studies have demonstrated the presence of TCFAs in places
other than the culprit lesion or even culprit artery [16,36]. In fact,
we were subsequently able to conﬁrm this hypothesis, by demon-
strating that imaging characteristics of the non-culprit artery are
associated with increased risk of MACE within the current study
population [34]. Therefore, this study design allows us to investi-
gate whether the patient's burden and vulnerability of athero-
sclerotic disease e as reﬂected by the phenotype of a non-culprit
artery segment e is associated with blood biomarkers [16]. Finally,
although the spatial resolution of IVUS-VH is formally too low to
detect thin caps, we have demonstrated that VH-IVUS derived TCFA
lesions strongly and independently predict the occurrence of MACE
within the current study population [34].
In conclusion, this study provides new insights into the role of
plasma CysC and NGAL in coronary atherosclerosis. Most impor-
tantly, it shows that in patients with normal kidney function, those
with higher CysC levels have fewer high-risk coronary lesions,
while in patients with impaired kidneys, those with higher CysC
have higher risk of MACE. Thus, this study implies that mild-to-
moderate kidney dysfunction modiﬁes the relationship between
plasma CysC and coronary artery disease. This has not been
established before, and it offers an explanation for the difference in
ﬁndings observed in experimental and epidemiologic studies. With
regard to cardiovascular risk prediction, CysC showed predictive
capacities when eGFRCr was below 90 ml/min/1.73 m2, whereas
NGAL levels were not predictive of MACE.
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